AbsTrACT background colorectal cancers are the third most common cancers in women and men in the USa. While dietary and lifestyle factors such as Western diet, physical inactivity and obesity have been linked to an increased risk of this malignancy, the mechanisms for these associations are unclear. gi hormones, including ghrelin, are involved in energy balance by mediating appetite and metabolism; however, the association between ghrelin and colorectal cancer has not been studied. Methods We conducted a case-control study nested within the all-male alpha-tocopherol, Beta-carotene cancer Prevention Study of Finnish smokers (aged 50-69 years) to examine serum ghrelin concentration and colorectal cancer risk. Data from 284 colon and 239 rectal cancers and 523 controls (matched on age, date of blood draw and serum availability) were analysed. Ors and 95% cis were calculated using multivariable (conditional) logistic regression. results Overall, low-serum ghrelin was significantly associated with increased risk of colorectal cancer (Q1 vs Q4: Or:1.57, 95% ci 1.05 to 2.34). For individuals developing tumours within 10 years of blood draw, those in the lowest quartile of serum ghrelin concentrations were statistically significantly more likely to develop colorectal cancers than those with higher serum ghrelin concentrations (Or: 10.86, 95% ci 5.01 to 23.55). However, for individuals with tumours developing more than 20 years after blood draw, low-serum ghrelin concentrations were associated with a decreased risk of colorectal cancer relative to those with the highest serum ghrelin concentrations (Or: 0.26, 95% ci 0.11 to 0.64). Conclusion low-serum ghrelin was associated with an increased colorectal cancer risk within 10 years of blood draw with a decreased risk for developing colorectal cancer more than 20 years after blood draw. these results suggest that ghrelin concentrations may vary across the carcinogenic process.
InTroduCTIon
Worldwide, colorectal cancers (CRC) are the third most common incident cancers in men and the second most common in women; 694 000 people died of this cancer in 2012, making it the fourth most common cause of cancer death. 1 Dietary and lifestyle risk factors, such as Western diet, physical inactivity and obesity, have been linked to an increased risk of CRC C2-4 ; the mechanisms behind these associations are unclear, but metabolic syndrome, insulin resistance, adipoctyokines and other inflammatory agents have been investigated. 5 Less is known about how GI hormones may influence, or be influenced by, carcinogenesis in the GI tract. Ghrelin is a hormone produced in the stomach. Previous work by our group and others has shown that low-serum ghrelin, measured years before diagnosis, is associated with substantially increased risk of oesophageal cancer (both squamous cell carcinoma and adenocarcinoma), oesophagogastric junctional adenocarcinoma and non-cardia gastric adenocarcinoma. [6] [7] [8] Ghrelin is known to have a variety of metabolic functions which range from stimulation of gastric acid and regulation of GI tract motility to control of appetite. 9 Ghrelin may also modulate long-term energy balance, mediating fatty acid metabolism and promoting fat storage. 9 significance of this study ► The GI tract is the largest endocrine organ in the body, though prospective studies exploring the association between GI hormones and GI carcinogenesis are limited. ► Ghrelin is a hormone produced in the stomach which is known to have a variety of metabolic functions which range from stimulation of gastric acid and regulation of motility to control of appetite. Ghrelin concentrations might be altered in conditions of chronic inflammation. ► Low-serum ghrelin concentrations have been associated with an increased risk of development of oesophageal and gastric cancers in prospective studies. ► Individuals with low-serum ghrelin concentrations had a 10-fold increase in risk of colorectal cancers for tumours developing within 10 years of blood draw. ► Conversely, for individuals with tumours developing more than 20 years later, low-serum ghrelin concentration was associated with a significantly decreased risk of colorectal cancer. ► Ghrelin concentrations may vary across the carcinogenic process, and this variation may have clinical utility. Further studies are required to replicate these findings and explore the association between ghrelin across the natural history of colorectal cancer.
Colon
Conditions such as chronic inflammation, insulin resistance and diabetes, all associated with an increased risk of C, alter serum ghrelin levels, 9 10 which may further promote inflammation and carcinogenesis within the lower GI tract.
Though serum ghrelin has been investigated for its role in cachexia among patients with CRC 11 it is not yet known whether serum ghrelin levels are associated with the development of colorectal cancer. We therefore investigated the association between serum ghrelin concentration and subsequent risk of CRC in a case-control study nested within the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study.
MeThods
Subjects were drawn from the ATBC Study, a randomised, doubleblind placebo-controlled, primary prevention trial designed to determine whether daily supplementation with alpha-tocopherol (50 mg/day), beta-carotene (20 mg/day) or both would reduce the incidence of lung and other cancers in male smokers. 12 Between 1985 and 1988, 29 133 eligible Finnish male smokers between 50 and 69 years old were recruited to the ATBC Study. The trial ended in 1993; however, participants continue to be followed as a cohort. This study was approved by the institutional review boards of both the National Institutes of Health in the United States and the National Public Health Institutes in Finland. All participants provided written informed consent.
All case subjects had incident colon or rectal adenocarcinoma (International Classification of Diseases Ninth Revision (ICD9) codes 153.0-153.4, 153.6-153.9, 154.0-154.3, diagnosed through 31 December 2011) defined according to the ICD9. We selected only first incident primary colorectal cancer (CRC) cases (n=529). For patients diagnosed through 30 April 1999, two study physicians reviewed medical records for diagnostic confirmation and staging, and one pathologist reviewed histopathological or cytological specimens when available. Information on patients with CRC diagnosed since May 1999 was derived solely from the Finnish Cancer Registry, which provides almost 100% tumour ascertainment for the ATBC cohort. 13 Controls had to be alive and cancer free at the time of case diagnosis and had available serum insulin and glucose data. Using incidence density sampling, controls were matched to cases on age at randomisation (±1 year), date of blood draw (±30 days) and serum sample availability.
data collection
Participants completed questionnaires at baseline regarding general risk factors, medical history and dietary intake. Dietary intake was assessed using a food frequency questionnaire, asking about usual food consumption over the previous year, including 276 common foods and mixed dishes, using a picture booklet to aid estimation of portion size. 14 15 The food frequency questionnaire was satisfactorily completed by 27 110 participants (93%) at study entry. The weight and height of all participants was measured by trained study staff. Fasting (overnight) blood samples were collected from participants at baseline (1985) (1986) (1987) (1988) and serum samples were stored at −70°C.
Laboratory analysis
Two hundred and eighty-four cases of incident colon cancer had adequate serum samples for ghrelin analysis, as did 239 cases of rectal cancer cases and 523 controls. Total ghrelin was measured by radioimmunoassay using reagents obtained from Millipore Linco Research (St Charles, MO). This assay uses an antibody that is specific for total ghrelin and 0.1 mL of serum in a 2-day disequilibrium assay. Using 96 blinded quality control samples (six per batch) from a single serum pool from the ATBC Study, the coefficient of variation across all batches for these assays was calculated as 23%.
statistical analysis
Statistical analyses were performed using STATA V.10.1 (Stata Corp) and all p values were two sided. The distributions of baseline characteristics across cancer cases relative to controls were compared using Student's t-tests for continuous variables and Pearson's χ 2 tests for categorical variables. The associations between baseline characteristics and serum ghrelin quartile were determined using a non-parametric Wilcoxon-type test for trend for continuous variables and the Mantel-Haenszel trend test for categorical variables.
OR and 95% CI for associations between serum ghrelin concentration and risk of colorectal cancers, as well as colon and rectum subsites, were calculated using unconditional logistic regression models. Estimates derived from conditional and unconditional logistic regression models were similar, and as such, only the results of the unconditional models, which offered more precise risk estimates, are presented within this manuscript. When we modelled ghrelin as a continuous variable, the estimates were scaled to 176 pg/mL (½ the IQR observed in controls: (Q3-Q1)/2). Preliminary analysis included a squared term for ghrelin, however, the fit of this model was equivalent to that of the model with no squared term. Categorical analyses examined the data in quartiles (of serum ghrelin levels in the controls), using the fourth quartile (highest values) as the referent group. Multivariable models of risk were adjusted for: age at randomisation, total years of smoking, total cigarettes/day, alcohol (g/day), body mass index (BMI; kg/m 2 ), intake of fruit (g/day) and vegetables (g/day), total dietary fibre (g/day), education (postprimary school), consumption of red meat (g/day) and processed meat (g/day), diabetes (either self-reported history of diabetes or blood glucose ≥126 mg/dL), analgesic drug use daily >1 month (yes/no) and ATBC treatment group assignment (alpha-tocopherol, beta-carotene, both or neither). Total caloric intake was included in preliminary models but did not significantly alter estimates and was therefore omitted in favour of a more parsimonious model. P trend were calculated by performing a non-parametric test for trend (across ghrelin quartiles for each baseline characteristic). 16 Stratified analysis examined associations by BMI category (BMI <or ≥ 25 kg/m 2 ) and smoking (</≥median total cigarettes/ day and </≥median total years of smoking). Lag analysis was also performed: cancer cases were classified according to whether they occurred within 10 years of baseline, between 10 and 20 years of baseline or more than 20 years after baseline. The food frequency questionnaire was completed satisfactorily by 93% of study participants. Participants who were missing dietary data were included in the analyses with an indicator variable for missing.
resuLTs
Baseline characteristics of the cases and controls are shown in table 1. Colon and rectal cancer cases were more likely to have a blood glucose level above 126 mg/dL. Colon cancer cases tended to consume more alcohol than controls. Rectal cancer cases were less likely to report a history of diabetes than controls. There were no other differences in baseline characteristics between cases and controls. Baseline characteristics were also examined by serum ghrelin concentration among controls only; this Colon revealed that ghrelin was marginally associated with fruit intake (table 2) but not with any other characteristics.
Lower baseline serum ghrelin (as a continuous variable scaled to 176 pg/mL, ½ the interquartile range of serum ghrelin in the controls) was not statistically significantly associated with an increased risk of either colon or rectal cancer (table 3) .
However, modelling the data using categorical variables and using the highest quartile as the referent group, the risk of colorectal cancer increased significantly from the highest to the lowest quartile of serum ghrelin. Following multivariable adjustment (which had little effect on our estimates), those in the lowest quartile of serum ghrelin had a statistically significant increase in risk of colorectal cancer relative to those in the highest quartile of serum ghrelin (OR Q1 vs Q4 :1.57; 95% CI 1.05 to 2.34; P trend =0.03). This association was significant for rectal cancer (OR Q1 vs Q4 :2.14; 95% CI 1.13 to 4.03, P trend =0.01), but not for colon cancer (OR Q1 vs Q4 :1.37; 95% CI 0.78 to 2.40, P trend =0.38).
We then undertook lag analyses to assess the association between serum ghrelin levels and colorectal cancer across more than 20 years of follow-up within the ATBC Study (table 4). Analyses were Colon stratified according to whether tumours developed within 10 years of blood draw, between 10 and 20 years or more than 20 years after blood draw. Surprisingly, we observed substantial differences in the associations between low-serum ghrelin and cancers occurring in each time period. Mean serum ghrelin concentrations in colorectal cancer cases varied significantly over time from 541 pg/ mL (SD: 172 pg/mL) for tumours developing within 10 years of blood draw to 824 pg/mL (SD: 439 pg/mL) for tumours developing between 10 and 20 years later and 896 pg/mL (SD: 334 pg/mL) for those developing more than 20 years later (figure 1: serum ghrelin concentration over time in colorectal cancer cases). Low-serum ghrelin (Q1 vs >Q1) was associated with a 21-fold increase in risk of colon cancer (OR: 21.00, 95% CI 5.08 to 86.75) and a sevenfold increase in risk of rectal cancer (OR: 6.80; 95% CI 2.65 to 17.39) occurring within 10 years of blood draw (CRC: 10.86; 95% CI 5.01 to 23.55). For cancers occurring between 10 and 20 years of blood draw, we found no statistically significant associations between serum ghrelin concentrations and risk of either colon or rectal cancer. However, low-serum ghrelin was associated with a statistically significant decrease in risk of both colon (OR: 0.33, 95% CI 0.11 to 1.03) and rectal (OR: 0.18, 95% CI 0.04 to 0.82) cancers occurring more than 20 years after blood draw (CRC: 0.26; 95% CI 0.11 to 0.64). We observe consistent associations when examining time between blood draw and diagnosis in 2-year intervals; the majority of cases with a shorter length of follow-up were more likely to be in the lowest quartile of serum ghrelin (table 5) . The lag analysis was repeated, this time excluding those cases which developed within 2 years of baseline (n=35) and association remained (CRC: OR: 9.17; 95% CI 3.96 to 21.29). Stratified analyses for BMI (<or ≥ 25 kg/m 2 ) and smoking (<or ≥ median for total cigarettes/day and total years smoking) did not significantly alter risk estimates (data not shown).
dIsCussIon
In this nested case-control study within the ATBC Study cohort of male smokers aged between 50 and 69 years old, we report ORs are scaled to 176 pg/mL, which is ½ of the interquartile range in the controls (75th percentile-25th percentile ÷ 2) and interpreted as the change per unit decrease in serum ghrelin. †Adjusted ORs and 95% CIs were calculated using models which included: age at randomization, education (postprimary school), total years of smoking, total cigarettes/day, BMI (kg/m 2 ), diabetes (either self-reported history of diabetes or blood glucose ≥126 mg/dL), daily analgesic use for >1 month (yes/no), alcohol (g/day), red meat consumption (g/ day), processed meat consumption (g/day), fruit intake (g/day), vegetable intake (g/day), total dietary fibre (g/day) and ATBC treatment group assignment. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; BMI, body mass index. Table 4 ORs and 95% CIs (unadjusted conditional logistic regression) for the association between low (Q1:<576 pg/mL) or continuous serum ghrelin concentration and colorectal cancer in the ATBC Study by number of years between blood draw and diagnosis *Continuous ORs are scaled to 176 pg/mL, which is one half of the interquartile range in the controls (75th percentile-25th percentile ÷ 2) and interpreted as the change per unit decrease in serum ghrelin. ATBC, ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention.
Colon a statistically significant increase in risk of developing colorectal cancer for individuals with lower levels of serum ghrelin at baseline. This statistically significant association was confined to cancers which occurred earlier (within 10 years of blood draw) in the study, conversely there was a statistically significant positive association for colorectal cancers occurring later in the study (>20 years from blood draw). These results suggest that the association between ghrelin concentrations and colorectal cancer risk may vary across the carcinogenic process. We can find no prospective studies of ghrelin and colorectal cancer in the literature; in fact, we have identified just four previous studies of ghrelin and any GI cancers. A study nested within a multiphasic health check-up cohort in the Kaiser Permanente Medical Care Programme (California) analysed serum ghrelin concentrations among oesophageal adenocarcinoma cases and matched controls and found a fivefold increase in risk of oesophageal adenocarcinoma for those in the lowest quartile of serum ghrelin. 8 In a previous prospective analysis from the ATBC Study cohort, we reported a fivefold increase in risk of gastric non-cardia adenocarcinoma and oesophagogastric junction adenocarcinoma among individuals in the lowest quartile of serum ghrelin, compared with those in the highest. 7 Further, we identified close to a sevenfold increase in risk of developing oesophageal squamous cell carcinoma, again in the ATBC Study, for those individuals in the lowest relative to the highest quartile of serum ghrelin. 6 In this previous study, the baseline serum ghrelin concentrations in controls were almost identical in range to those seen here. Lastly, a cross-sectional case-control study of gastric cancer (non-cardia and cardia), oesophageal adenocarcinoma and oesophageal squamous cell carcinoma within the Aras Gastrointestinal Health Survey (Iran) 17 also reported a statistically significant inverse relationship between serum ghrelin and gastric cancer (both non-cardia and cardia) and oesophageal squamous cell carcinoma, although no significant association was found with oesophageal adenocarcinoma. Together, these reports indicate that low-serum ghrelin levels are significantly associated with risk of all four major upper GI cancers: non-cardia gastric adenocarcinoma, gastric cardia/oesophagogastric junctional adenocarcinoma, oesophageal adenocarcinoma and oesophageal squamous cell carcinoma, despite differing aetiological and risk factor profiles across these four sites. Our current analysis suggests that ghrelin Colon may have a more nuanced role in the aetiology of lower GI cancers relative to upper GI cancers. Surprisingly, however, we observed a complicated association between ghrelin and colorectal cancer. Whereas low ghrelin was associated with an increased risk among cancers occurring within 10 years of blood draw, it was associated with a decreased risk in cancers occurring more than 20 years after blood draw. Although such associations are intriguing, they should be interpreted cautiously: not only are they a surprise, but ours is the first study to investigate the association and it could be a chance finding. Each of our previous investigations (oesophageal squamous cell carcinoma, gastric cardia and non-cardia adenocarcinoma) had outlined a very consistent inverse association for each time period. However, we do note that there is prior evidence of ghrelin having both a pro-proliferative and antiproliferative effect in tissue culture studies based on varied cell lines and varying conditions. 18 It seems possible that ghrelin might act differently, in terms of inflammation and proliferation, depending on the stage of tissue carcinogenesis: normal tissue, adenoma or tumour. It is also possible that the metabolic repercussions of low-serum ghrelin may contribute to a pro-carcinogenic environment during cancer initiation while the pro-inflammatory effect of low-serum ghrelin may enhance subsequent tumour development. Low ghrelin may also be the result of reverse causation, if the tumour is somehow inhibiting the secretion of ghrelin as a result of altered hormonal signals as a consequence of changing histology.
The prospective design of our study is one of its major strengths because it not only allowed the use of baseline prediagnostic serum, obtained following an overnight fast, for analysis of ghrelin, but it also provides more than two decades of follow-up to assess cancer development. The ATBC Study also includes substantial covariate information that allowed for adjustment for potential confounders. Additionally, Finland has an excellent population-wide cancer registry so that loss to follow-up is minimal; similarly, migration within this cohort is also minimal. Our study also had limitations. The ATBC Study only recruited male smokers, and as such, the generalisability of our findings may be limited, but in this study, we found that smoking (either intensity or duration) did not alter the observed associations (data not shown). Clinical characteristics such as tumour stage and grade were unavailable for the majority of colorectal cancer cases in our study. Also, we measured total ghrelin, but there are two isoforms of ghrelin: acylated ghrelin, which binds to the growth hormone secretagogue receptor 1a, and desacylated ghrelin. In the stomach, desacylated ghrelin is present in levels that are three times higher than acylated ghrelin. Desacyl ghrelin was initially thought to be biologically inactive, but recent evidence suggests that this is not the case. 19 Further studies are needed to determine the significance of acylated and desacylated ghrelin in the context of GI cancer disease. The subgroup analyses of colon and rectal tumours by lag time were underpowered and should be interpreted with caution, although results were similar for both sites, future studies are needed to replicate these findings. Lastly, we measured ghrelin at one time-point only, and our results emphasise the need for measurement at multiple time-points over very long periods of time, which we hope may be addressed in future studies. We note that a previous study in (obese) children found that fasting serum ghrelin concentrations were remarkably consistent when measured 1 year apart. 19 In this prospective investigation, we found that low-serum ghrelin concentrations were associated with a statistically significant increase in risk of both colon and rectal cancer for tumours developing within 10 years of blood draw and a statistically significant decrease in risk of cancer for those developing more than 20 years after blood draw. These intriguing results suggest that ghrelin concentrations may vary across the carcinogenic process and that in addition to an aetiologic role, ghrelin may serve as a marker of altered GI physiology.
